GlassScriptPhysician profile
Joseph T Gillespie
NPI 1669589164
$7,878.82
in general payments reported to CMS, 2019-2025
34 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,923 · 2020: $506 · 2021: $822 · 2022: $2,049 · 2023: $996 · 2024: $131 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144 · Travel and Lodging: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.80 |
| Travel and Lodging | $435.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,898.37 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Vertiflex, INC. | $1,485.69 | 2019 | |
| Medtronic USA, INC. | $1,002.76 | 2019-2020 | |
| Stryker Corporation | $890.50 | 2023 | Augment Injectable, Spinejack, Ivas |
| Boston Scientific Corporation | $683.19 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $378.22 | 2019 | |
| Foundation Fusion Solutions, LLC | $216.55 | 2021 | |
| Globus Medical, INC. | $182.18 | 2025 | Vyrsa V1, Senza |
| Spr Therapeutics, INC | $157.69 | 2025 | Sprint Pns System |
| Stimwave Technologies Incorporated | $119.21 | 2021 | |
| Arbor Pharmaceuticals, INC. | $74.01 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $64.23 | 2020 | |
| Relievant Medsystems, INC. | $58.70 | 2022-2023 | Intracept |
| Nevro Corp. | $57.72 | 2021-2024 | Senza |
| Biodelivery Sciences International, INC. | $57.07 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $55.63 | 2019 | |
| Saluda Medical Americas, INC. | $49.42 | 2025 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.49 | 2020 | |
| Si-Bone, INC. | $47.83 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $44.02 | 2021 | |
| Scilex Pharmaceuticals INC. | $40.44 | 2019 | |
| Daiichi Sankyo INC. | $35.64 | 2019 | |
| Redhill Biopharma INC. | $31.23 | 2020-2022 | |
| Assertio Therapeutics, INC. | $27.48 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.36 | 2023 | Exparel, Iovera, Zilretta |
| Valinor Pharma, LLC | $20.81 | 2024 | Movantik |
| Abbott Laboratories | $18.58 | 2024 | Eterna |
| Collegium Pharmaceutical, INC. | $18.52 | 2023 | Belbuca |
| Amgen INC. | $17.55 | 2019 | |
| Fidia Pharma USA INC. | $16.57 | 2024 | Triluron, Hymovis, Hyalgan |
| Idorsia Pharmaceuticals US INC | $15.21 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.07 | 2025 | |
| Nalu Medical, INC. | $13.60 | 2021 | |
| Ibsa Pharma INC. | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.